---
title: Current myeloproliferative neoplasm scoring systems for clinical practice
date: '2024-10-30'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39476004/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20241030210336&v=2.18.0.post9+e462414
source: Blood
description: BCR::ABL1-negative myeloproliferative neoplasms (MPN) are clonal hematological
  malignancies resulting from the proliferation of myeloid cells harboring a JAK-STAT
  pathway activating driver mutation. MPN management recommendations are based on
  the evaluation of different risks to prevent disease evolution associated events
  while preserving patients' quality of life. Such risks can be common across all
  MPN or specific to each subtype (polycythemia vera (PV), essential thrombocythemia
  ...
disable_comments: true
---
BCR::ABL1-negative myeloproliferative neoplasms (MPN) are clonal hematological malignancies resulting from the proliferation of myeloid cells harboring a JAK-STAT pathway activating driver mutation. MPN management recommendations are based on the evaluation of different risks to prevent disease evolution associated events while preserving patients' quality of life. Such risks can be common across all MPN or specific to each subtype (polycythemia vera (PV), essential thrombocythemia ...